F S&P 500
5,207.50 -5.25 (-0.10%) F Dow Jones
39,165.00 -30.00 (-0.08%) F Nasdaq
18,155.25 -31.25 (-0.17%) E-mini Russell 2000 Index Futur
2,059.90 -4.90 (-0.24%) Petróleo
79.42 +0.43 (+0.54%) Oro
2,320.90 -1.40 (-0.06%)
Centessa Pharmaceuticals plc (CNTA)
Fuera de horario:
Centessa Pharmaceuticals plc
1 Ashley Road
3rd Floor
Altrincham WA14 2DT
United Kingdom
https://www.centessa.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 76
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Saurabh Saha M.D., Ph.D. | CEO & Director | 1.04M | N/D | 1976 |
| Dr. David M. Chao Ph.D. | Chief Administrative Officer | 710.3k | N/D | 1968 |
| Dr. Antoine Yver M.D., M.Sc. | Executive VP & Chairman of Development | 773.14k | N/D | 1958 |
| Dr. Gregory M. Weinhoff M.B.A., M.D. | Principal Accounting Officer & CFO | 655k | N/D | 1971 |
| Ms. Tia L. Bush | Chief Technology & Quality Officer | N/D | N/D | 1971 |
| Ms. Kristen K. Sheppard Esq., J.D. | Senior Vice President of Investor Relations & Corporate Communications | N/D | N/D | N/D |
| Mr. Iqbal J. Hussain L.L.B. | General Counsel, Chief Compliance Officer & Corporate Secretary | N/D | N/D | 1981 |
| Ms. Karen M. Anderson | Chief People Officer | N/D | N/D | 1968 |
| Dr. Harris L. Rotman Ph.D. | Senior Vice President of Regulatory Affairs | N/D | N/D | N/D |
| Dr. Patrick Yue M.D. | Senior VP of Clinical Development & Innovative Medicines | N/D | N/D | N/D |
Descripción
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.
Gestión corporativa
La calificación ISS Governance QuickScore de Centessa Pharmaceuticals plc a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
